| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年4月 |
Immune Repertoire Sequencing Market – Global Forecast to 2030
The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period.
世界の免疫レパートリーシークエンシング（IRS）市場は、予測期間中に 9.6% の CAGR で成長し、2025 年の 3 億 3,400 万米ドルから 2030 年には 5 億 6,500 万米ドルに達すると予測されています。
This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes.
この市場は、技術の進歩により免疫測定に基づく研究ソリューションの効率、感度、拡張性が向上し続ける中で成長しています。NGS統合、自動液体処理システム、ハイスループットスクリーニングプラットフォームなどの革新により、より迅速かつ正確なアッセイ結果が可能になります。これらの進歩によりワークフローが合理化され、手作業によるエラーが削減され、スループットが向上するため、IRSテクノロジーは研究および臨床アプリケーションにおいてよりアクセスしやすく、信頼性の高いものとなっています。さらに、個別化医療および精密医療への注目が高まる中で、医療提供者や研究者は特定のバイオマーカーを検出し、個々の患者に合わせた治療を行うツールをますます必要としており、IRSソリューションの需要が高まっています。標的療法への移行は、コンパニオン診断、治療モニタリング、個別化治療戦略をサポートするように設計された特定のアッセイキットおよび試薬の開発を促進します。その結果、臨床的意思決定を導き、治療結果を向上させるために、正確で患者中心のデータを提供できる免疫測定テクノロジーのニーズが高まっています。
List of Companies Profiled in the Report:
- Illumina, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- PacBio (US)
- Oxford Nanopore Technologies PLC (UK)
- 10X Genomics (US)
- QIAGEN (Netherlands)
- Agilent Technologies (US)
- Danaher Corporation (US)
- Takara Bio Inc. (Japan)
- Adaptive Biotechnologies (US)
- BGI Group (China)
- Tecan Trading AG (Switzerland)
- Azenta US Inc. (US)
- Personalis, Inc. (US)
- Creative Biolabs (US)
- Celemics, Inc. (South Korea)
- CellCarta (Canada)
- iRepertoire, Inc. (US)
- New England Biolabs (US)
- Cerba Research (Belgium)
- CeGat GmbH (Germany)
- Element Biosciences (US)
- Seqalis (Belgium)
- Synbio Technologies (China)
- MedGenome (US)
- Enpicom (Netherlands)
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing technological advancements, growing focus on precision/personalized medicines, increasing use of IRS in organ transplantation), restraints (need for high capital investments), opportunities (integration of AI and ML in IRS), and challenges (variations in regulatory frameworks and international trade dynamics) influencing the growth of the immune repertoire sequencing market.
- Product/ Service Development/Innovation: Detailed insights on upcoming technologies and new product and service launches in the immune repertoire sequencing market
- Market Development: Comprehensive information about lucrative markets – the report analyses the immune repertoire sequencing market across varied regions.
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the immune repertoire sequencing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product and service offerings of leading players in the immune repertoire sequencing market.